Moffitt Cancer Center Researchers Identify Gene Variations in Lung Cancer Patients That May Help Predict an Individual's Treatment ResponseAugust 09, 2013
TAMPA, Fla. - Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in non-small cell lung cancer patients that can help predict survival and treatment response. Their findings could help lead to more personalized treatment options and improved outcomes for patients.
The researchers analyzed DNA sequence variations in 651 non-small cell lung cancer patients, paying close attention to 53 inflammation-related genes. They found that four of the top 15 variants associated with survival were located on one specific gene (TNFRSF10B). In the study, these variants increased the risk of death as much as 41 percent. The researchers also found that patients with these gene variations had a greater risk of death if their treatment plans included surgery without chemotherapy compared to patients who were treated with chemotherapy following surgery.
"There are few validated biomarkers that can predict survival or treatment response for patients with non-small cell lung cancer," said study lead author Matthew B. Schabath, Ph.D., assistant member of the Cancer Epidemiology Program at Moffitt. "Having a validated genetic biomarker based on inherited differences in our genes may allow physicians to determine the best treatments for an individual patient based on their unique genetics."
Lung cancer is the leading cause of cancer-related deaths in the United States for both men and women. Additionally, non-small cell lung cancer represents more than 80 percent of lung cancer diagnoses.
"Non-small cell lung cancer has an extremely poor five-year survival rate. Only about 16 percent of all patients survive for five years and tragically, only about four percent of patients with late stage disease live longer than five years," explained Schabath. "Part of the difficulty in treating lung cancer is the genetic diversity of patients and their tumors. Using a personalized medicine approach to match the best treatment option to a patient based on his or her genetics will lead to better outcomes."
The researchers noted that there has been no published data examining the association of these four specific variants on cancer risk or outcome, although studies have reported associations with other gene variants in the same gene family as TNFRSF10B.
The study can be found in the July issue of Carcinogenesis.
The work was supported by funding from the State of Florida through the James & Esther King Biomedical Research Program (09KN-15), a National Institutes of Health SPORE grant (P50 CA119997), an American Cancer Society grant (93-032-13), and a grant from the National Cancer Institute (5 UC2 CA 148322-02).
Moffitt Cancer Center
Related Lung Cancer Current Events and Lung Cancer News Articles
Precision prevention of colorectal cancer
Precision medicine's public face is that of disease -- and better treatments for that disease through targeted therapies.
Plasma genotyping to predict treatment benefit in patients with NSCLC
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.
Study shows how TRK-fusion lung cancer escapes LOXO-101, offering new treatment strategies
A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101, a kinase inhibitor of the TRK-fusion genes that drive a subset of cancers.
Precision medicine brings new hope to those with advanced urothelial cancer
Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.
Cancer research at Marshall University shows promise for combating deadly lung cancer
A study by researchers at Marshall University Joan C. Edwards School of Medicine has found that blocking the blood supply of small cell lung cancer tumors may help reduce their growth and delay the regrowth process after treatment. Small cell lung cancer is considered the most lethal of all lung cancers.
Nanoparticles deliver anticancer cluster bombs
Scientists have devised a triple-stage "cluster bomb" system for delivering the chemotherapy drug cisplatin, via tiny nanoparticles designed to break up when they reach a tumor.
New tool mines whole-exome sequencing data to match cancer with best drug
A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer's unique genetics to FDA-approved targeted treatments.
Statement published on pairing smoking cessation with lung cancer screening
Researchers, including an associate professor from the Medical University of South Carolina Hollings Cancer Center, say smokers who go to a doctor to be screened for lung cancer should also be encouraged to quit smoking during their visit.
CRI researchers link absence of protein to liver tissue regeneration
Scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals.
Beyond DNA: TGen points the way to enhanced precision medicine with RNA sequencing
Uncovering the genetic makeup of patients using DNA sequencing has in recent years provided physicians and their patients with a greater understanding of how best to diagnose and treat the diseases that plague humanity. This is the essence of precision medicine.
More Lung Cancer Current Events and Lung Cancer News Articles